No takes yet. Share an insight, caveat, or question.
Experimental model reveals lgals3 enhances erk1/2 activation in liver fibrosis, suggesting new antifibrotic targets.
Zheng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: